ERS-ATS COPD Guidelines

صفحه 1:
ECRG-OTG COPO Gurdetices Ovpyrtht © Gurvpews Respirupry Onviey COOS ‏سم‎ 2 ۹7 

صفحه 2:
6 (0 1 ‎ice Ua aA Ucar ( @1O(nO) ca‏ 0ت ‎he ed ANG cua R IN RNS as ea a cia‏ ۱ ‎NS a OM CE A nN ace‏ ‎I a UUM NCL Nn ast SACL A ara acca aN 0 oe CAN ert oe Ag ome a aa Ua ۱ ‎ ‎ 

صفحه 3:
Cy Crea )60( 06 rane fae NSCs PAR ira Dea Ne NNN aoa 0 DN Boal ed ALENT NEN Ca Aa ۱ ‏وم‎ ENN Cm Ne IN aa INOS cae ol Nd ON Nas acts LOCO cad AS cat RAO Se SNe rea I Boma Ne eae VaR 2 Zac as RS INCL CaS Colm ca ‏وس مد‎ 

صفحه 4:
Crate = Te TT ee ee aes CCR) ‏وت یه‎ COP O wortdliy ta Pewdes kas wore thao doubled ‏روت تا‎ aan 

صفحه 5:
(OOO en enters Yi creed whee chee or Spt val ‏ا ل‎ ae ae Dobarey sxovke ts by Par the covet eportant risks Barter Por OOP O workhuide. ‏موی سیم ترا‎ 

صفحه 6:
Mc cd ‎RRL Cotr a‏ سا ‎eee‏ 0 ‏اه عسو اه مورا مه ‎Sd a‏ ‎et‏ اس مس سس سای ی ‎Coro.‏ ‏مت سس ها 1 ‎Pe a ond ed ee oe he eee ee TOL NO‏ ‎porn bee ee eee,‏ اما لجه متا رنه ‎auten eee an‏ جد ‏ا ‎ 

صفحه 7:
(0) 0000 2 ععسم0) سم وا مت رس من مرت رت ۱۱۱ ات ات دا eta 0 0 eal 0 بونتصلام ا جداا جلاب ججمجعهج أن وا لججقاحام ججا اوداك برصاو معام 8) 3 | ‏اي‎ ee eer ee ‏ةا "ا‎ re eee eee Loge nent Een OEE CRT are tr teats Coren 

صفحه 8:
Dingess oP CORPO (C) ۹ 7 ۱۳ ‏ار وت پم متسه‎ را ‎kertatiza trot i ot Bully reversble.‏ [ @osbrovhodkicr ۳600 % prod 0/00 

صفحه 9:
CNN ‏مه‎ PANT (4) ea eel ne OR ka | oe Ce RR ae Loc ecm eee Ree nen Econ ae a eee er nd heuthvare systew. ‎a ka‏ سر توا لا ‏صاب توصو و و ماه له رام ‎ ‏قو و ی ما وت رام ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ 

صفحه 10:
۱۹ oP stable COPO ۱ ‏و مس مر‎ ‏اس مرس مت م۱۳‎ CON rea aU NEL NPAT ‏و(‎ ا ار مت ‎CT acta)‏ 

صفحه 11:
‎Oucageweut ۱ ۱‏ 2 حدم مس مسمص دا اس مرس مت م۱۳ تس دم مس ‎CEN‏ ‎Outrtica‏ ‎Gurgery ia ond Por COPO‏ كدت اس مهو ‎ ‎ 

صفحه 12:
مر وت( يي ا م ا ل ا ۱۹ .مصتعص ذا بجأ جز ۱ ص۱۸۱ ‎NE aa aE. cM Cas) PAs cae CA Cee‏ ۱ Dke toholed route is prePerred. 

صفحه 13:
‎ea ©) ۱‏ السخد سح ‏رهم 6 ] تمهت مه ۱ ‎۱ em UCSC ia Ct ۱ ah aca ee ‎ORY ee caU RON can Cea NR at aN Ca ‏و‎ CARS CA CARLA ‎ON cee aa Cae oe SE as cao oo ۱ PL NC ‎ ‎ 

صفحه 14:
‎lOO‏ هت مت وم موم وت ‏ما مها اف ل الك ‎0 ‏ا‎ ee ‏و و ی مه‎ ke _ ‎| cae coke emia ‏اه مت سرت‎ ‏سس ابص مت وف هت تا یاف ماس و بت سای باون سب ]مس ‎ ‎ ‎ 

صفحه 15:
‎ca‏ () بسا امس اس ‎ONG eam‏ ‎CN rari rea ear ANS SCAN CLM ca aD ad ieee watery cosode, uthough their ePPevts ic COPM ‎CaS cacaccacal (Coad‏ ل ‎dossitied us oa PEOd <GO% precicted), there iz‏ ‎Nocona AN Enna cia Doan‏ ‎ ‎ 

صفحه 16:
& ‎Veale)‏ سس ‎Effects on commonly used medications on important clinical outcomes in COPD ‎Chor -avtiog Bugoutst Yeo (0) Yew (D) 2 OD ‎Yeo 0) ۸0‏ 0۵ص (0) مس و ‎Yeo (0) Yew (0) Yew) 0‏ 0 ‎Motrepiuce Yeo (0) Yew (0) Yew () 0‏ ‎Mikaled pontvesteronds Yeo (0) OD ‘ew (0) Yew ()‏ ‎‘keophylice Mew (BD) ex (®) Yew (0) Yew (0)‏ ‎Chon -uctiag Buqvtst Yes (0) Cowe ‎brosoide, ‘es )0( Cowe‏ مدب اتوص ابوط ‎Loay avtiay Bayoaists ( ‘Yes (0) rsitcral ‘ee (0) ‏اس‎ ‎ow Cowe ‘Yes (®) Aopen ‎ ‎ 

صفحه 17:
‎Oucageweut ۱ ۱‏ ام مس مس ص۱۳ ‎ae‏ ما تس دم مس ‎CEN‏ ‎Outrtica‏ ‎Gurgery ia ond Por COPO‏ كدت اس مهو ‎ ‎ 

صفحه 18:
ظ ۱ )0( 7 17۳۲ ‎mane‏ ری ۱۳ ا الل 02 ‎oe eA‏ م۱ ‎ea eS a AAS aL‏ ل ل لك ‎dhoxide (OO 5) retection.‏ ‏الس سيج لبس ب د اج 39109 ‎Oa Medios‏ ‎On a ae Re NO RN eC rica en cla ‎۱9 ogc AS aS ea Od ‎ ‎ 

صفحه 19:
‎Oucageweut ۱ ۱‏ ام مس مس ص۱۳ اس مرس مت م۱۳ نس تمه سم او ‎Outrtica‏ ‎Gurgery ia ond Por COPO‏ كدت اس مهو ‎ ‎ 

صفحه 20:
awe aren Oe eR ee ۳ ‏بب۰‎ ‎10 terete ees ones ec cee eee Pckovoey rekobitaica should be coastdered Por pateuts wil COPO whe | cer ee nc PES ee ig ee ee etd Eee ae ere 1۱ et ca ee eee See Ca ae اس جوم ور و موس Ce يي فا و ام مت امس میا 

صفحه 21:
‎Oucageweut ۱ ۱‏ ام مس مس ص۱۳ اس مرس مت م۱۳ تس دم مس ‎CEN‏ ‏نسم ‎Gurgery ia ond Por COPO‏ كدت اس مهو ‎ ‎ 

صفحه 22:
ON a act Qeth bes ced a depleicd of PotPree wore (PRO) way be observed to stable ۱9 ‏وا‎ يي ل ا وا مت وتا ‎CO a a nae‏ ‎cts ON ee een Rn Ra‏ ل ل ل الل ‎CN es i Me‏ مت 6001 >6 

صفحه 23:
‎Oucageweut ۱ ۱‏ ام مس مس ص۱۳ اس مرس مت م۱۳ تس دم مس ‎CEN‏ ‎Outrtica‏ ‎Guxpry to od Por COPO‏ كدت اس مهو ‎ ‎ 

صفحه 24:
۹ (0) ١ ۱ ‎mee‏ ار ‎OA el ea ee RS eC ee a nd ۱ a o ‎Ce Racca aR Rec mee Rao hema vo Pa) ۱ AMS BN oa CAC RN Ci aC ocr oct Dad 00000000 ‎aoe a ae‏ ل اي ل نوم ماوع مجه جرؤوج ناج لجه ‎LAS NNN NaS‏ جصامصامجوكمج با ‎ ‎ 

صفحه 25:
a Gurgery ia COP O (©) 1 Voax Oe eee ee Reene ee ce gen) ee eon cee ere eee eee oe eee Teena eee eed روت مروت شنت 

صفحه 26:
سس | اس اس 0۳0 مومس | | ‏تن‎ wae 

صفحه 27:
Surgery Por CORO (8) ‏امه‎ OT eran ee ean) ۳2 اسان سح ده سييست صصص لصب ‎ubich‏ 0[ یی سوت وس موی عون او اصح ال 0 سا دمجعه<) ماس اهاط مس6 463 ‎Chucr dyopore despte canal amie tear Almac kyperiracion (FBeymtoks‏ العا تقد ‎rckaon pukmoaany rekcbaeatos‏ ‎or coches‏ رجا میت ۱ ‎thoracte procecar‏ 0[ ‎Core‏ ‎(Chest ual deRorony‏ ‎red rd OO <M red‏ الا فا ‎ser bracket <M pred‏ 080{ مساو رو اس ‎Tepes‏ ‏0 ‏4ه 6< جلا ‎he (Wo. )‏ >05 ‎Olds (Darby)‏ > مجن يو باس مت اف امسر ‎SSS Se‏ وه ‎lowocrerky crac‏ تس نموه جرس امسج بايطا | سيد ‎Qho-wpperlobe predocnnend eearhyseere acd hike‏ ‎canara‏ موی ماه مه اماج سوير ی ‎a a a‏ ] ا ‎a Oe‏ ی ی eae 

صفحه 28:
۱۹ oP stable COPO ۱ ‏و مس مر‎ ‏اس مرس مت م۱۳‎ CON rea aU NEL NPAT ‏و(‎ ا ار مت ‎CT acta)‏ 

صفحه 29:
معدا ee eRe Le NOR ren Oe ace een caer eee Re ee ee ee eee eee cd ‏ی‎ eer Gleep quaity i worked) kopaired 1 CORO, boik subjectively oad cbieciuely. ۱ ene ‏جود (000001 علانب جامجادم‎ cater cn) 1 ee ee cee Oe enae ine on daar eee OOO nt ou teat Ne eee ee 00 0100 ‏ااا‎ er eee ee ace ‏ؤزؤزؤزؤز[ 0 ة‎ الروك ل ا 20 

صفحه 30:
‎Oucageweut ۱ ۱‏ ام مس مس ص۱۳ اس مرس مت م۱۳ تس دم مس ‎CEN‏ ‎Outrtica‏ ‎Gurgery ia ond Por COPO‏ كدت ‎al‏ ا ‎ ‎ 

صفحه 31:
46 Cae Caer’ 210,000 w (>FO,00O ‏رس‎ ee eo te ee ee OO Crores (8,0OO0-9,OOO Feet). Nhs is equivdedt tr oa 0 ‏و(‎ alien هار ار وت ۱9 ‎KPa).‏ از( ۱2 تام مت کاس مت مت ماس مت وی سم سم تم CO ‏لل‎ A a OME naa Cn ‎ae UN AMON BCA can MAC CAS A CANCCAN PA Cc]‏ اك ‎ ‎ 

صفحه 32:
۹ ‎MPa Oe aR acon)‏ اناك او مومسم تا سس سس 

صفحه 33:


صفحه 34:
۱ ca ‏ني الك‎ Nea a a RAN cd FN RS IRM cas cas feo cantons Ne cine Ua ea ea rae cs eae ۱ RNS et Cee a aN Oa Sn PaO ae] a chooge ia therapy. Oe ‏و ل‎ pe OES CAS MN cas 2 PAS ca eo ‏ا ل‎ Ne 

صفحه 35:
‎ca‏ لت مسر ,مس ای() ‎treutved (C)‏ ‎ON eae entra oda ‏ات ام اه هوجو‎ ۱ ۵20 Nas cal ‎Lak Serer eae cece ao arene ‏ری سس‎ Sor eee ae katona seepage ara ps Oeics: ‏بسن ماس سس تاش(‎ ‎0 ‏سس‎ ee ‎dine weg ‏اك ‎Oo See ‏“السدداات] ذا عدن جا ‎eet‏ جا حك ‎eri‏ ‎Ostet ‎1 ‎ 

صفحه 36:
Oates, acheter eed! 6 

صفحه 37:
)( ‏,ان‎ ۱ PASI eh ‏وا‎ (S) TA er Ee A a or ( 0096 > مسجت موه ریق 

صفحه 38:
۱۱ ۱ ‏وا‎ (O) 1۱9 ede ae ee ten] (Cher erhes fhe ‏سرت سس سا سم بات ۵ نو فج لحت (سحف حت لصف حك)‎ OF ٠١ Abe pete ea be urd, money (X01 nko, come amr Fat 

صفحه 39:
۹ ‎ACRE arate‏ اناك تیه مرس متا و ۱3 

صفحه 40:
AR a 17۳ Tet ae ee Cees ede acne re percee Laren (@a,0,) 4>90%. CO a ea es OR ECR ae a ee aie oe na ee ‏لجع‎ ree ۱ pam ae arte re CTO Ree ee a CeO ee صما لقحداد ( 87,0 ) ) بصعم هيت عطلح ربجا لسستجميب جد وماس قفد مجيعويت مج019 موه سای لو ول 0ك .و مدت وطامصام رن 00 وطاجصموصت مفجوجروا صجصا خأن مصامجر جة]) ‎Ue Oe tented Smee‏ ‎Oe ae eee cancers en cae‏ 

صفحه 41:
۹ ‏اناك‎ MPa Oe aR acon) ‏او مومسم تا‎ Te a 

صفحه 42:
‎ml‏ سس معا ‎0 ed ae ed gence ion coed ONO) ects aed ee cee ee eee] ‏ا ان رو هم مد‎ ea ‏ب 0000 ا‎ 001221211110116 ‎0 ‎[0 ee eee 0 hee a ee ‏.صقف‎ ‎0 eee te OORT pete ave ‎| nea ei eceeaed CACC ‎Cree) hen eaten ak ACO ‏.م‎ 000-016 RA ORO) tens ed ‏)اه سس سوه وم‎ On ‎ 

صفحه 43:
Ce ae ee) تم ما مت همم هت ۱ ‎ae‏ ارگ (xchisiva oniterta tackide: respirstory arrest, 0 تسس موسر ات 0 Se eer ete eae a eerie ed pec aah aceaesatas bate aes ota ea ‏مس همست‎ eae | eR OT Aa ee ae ON a Naa a a at ‏تس سس سس‎ 

صفحه 44:
۱ | [۳ bration of COPD Ce a a Rae ea ‏سم ها‎ La ROO ‏يا‎ 11597 16 ‘disconnection. 

صفحه 45:


صفحه 46:
4 ‎sad‏ اس مر لك او هس ‎CO itetieer eae‏ 00۰ 0( مسرت هه ی ‎CONT ea Beers aT ‎Inspiration ‎۳ ۱ oes eee eet ‏بذ‎ ‎559 1 ‎(eee ed ta AN ‏یم‎ ‎— ‏ی ی رس ی‎ ie 000 0 ‏ا‎ ‎ ‎ 

صفحه 47:
644۱060۱44 ۱6۳2۹6۳ و( ۱ و۱ ۱۲7/۲۶۱۲ Eur Respr JOOOP; CO: 99C-OFO 

ERS-ATS COPD Guidelines Copyright © European Respiratory Society 2005 These slides can be used freely for non-commercial purposes. ERS-ATS COPD Guidelines Definition of COPD  Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease state characterised by airflow limitation that is not fully reversible.  The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. ERS-ATS COPD Guidelines Epidemiology (1)  COPD is a leading cause of morbidity and mortality worldwide, and results in an economic and social burden that is both substantial and increasing.  Prevalence and morbidity data greatly underestimate the total burden of COPD because the disease is usually not diagnosed until it is clinically apparent and moderately advanced. ERS-ATS COPD Guidelines Epidemiology (2)  COPD is the fourth leading cause of death in the USA and Europe, and COPD mortality in females has more than doubled over the last 20 years. Leading causes of death in the USA, 1998 Heart disease Cancer Cerebrovascular disease (stroke) Number 724,269 538,947 158,060 Respiratory diseases (COPD) 114,381 Accidents Pneumonia and influenza Diabetes Suicide Nephritis Chronic liver disease All other causes of death 94,828 93,207 64,574 29,264 26,265 24,936 469,314 ERS-ATS COPD Guidelines Epidemiology (3)  COPD is a more costly disease than asthma and, depending on country, 50– 75% of the costs are for services associated with exacerbations.  Tobacco smoke is by far the most important risk factor for COPD worldwide.  Other important risk factors are: Host factors Exposures Genetic factors Sex Airway hyperreactivity, IgE and asthma Smoking Socio-economic status Occupation Environmental pollution Perinatal events and childhood illness Recurrent bronchopulmonary infections Diet ERS-ATS COPD Guidelines Pathogenesis and Pathophysiology  Pathogenesis    Tobacco smoking is the main risk factor for COPD, although other inhaled noxious particles and gases may contribute. In addition to inflammation, an imbalance of proteinases and antiproteinases in the lungs, and oxidative stress are also important in the pathogenesis of COPD. Pathophysiology  The different pathogenic mechanisms produce the pathological changes which, in turn, give rise to the physiological abnormalities in COPD:      mucous hypersecretion and ciliary dysfunction, airflow limitation and hyperinflation, gas exchange abnormalities, pulmonary hypertension, systemic effects. ERS-ATS COPD Guidelines Diagnosis of COPD (1)  Diagnosis of COPD should be considered in any patient who has the following:      symptoms of cough sputum production dyspnoea history of exposure to risk factors for the disease Spirometry should be obtained in all persons with the following history:    exposure to cigarettes and/or environmental or occupational pollutants family history of chronic respiratory illness presence of cough, sputum production or dyspnoea ERS-ATS COPD Guidelines Diagnosis of COPD (2) Spirometry  Spirometric classification of COPD:  Post-bronchodilator FEV1/forced vital capacity <0.7 confirms the presence of airflow limitation that is not fully reversible. Severity Postbrochodilator FEV1/FVC At risk FEV1 % pred >0.7 80 Mild COPD 0.7 80 Moderate COPD 0.7 50–80 Severe COPD 0.7 30–50 Very severe COPD 0.7 <30 Patients who: smoke or have exposure to pollutants have cough, sputum or dyspnoea have family history of respiratory disease ERS-ATS COPD Guidelines Smoking cessation (1)  Tobacco is the most important risk factor for COPD.  Cigarette smoking is an addiction and a chronic relapsing disorder.  Treating tobacco use and dependence should be regarded as a primary and specific intervention.  Smoking cessation activities and support for its implementation should be integrated into the healthcare system.  The key steps in intervention are: Ask Identify all tobacco users at every visit Advise Strongly urge all tobacco users to quit Assess Determine willingness to make a quit attempt Assist Help the patient with a quit plan, provide practical counselling, treatment and social support, recommend the use of approved pharmacotherapy Arrange Schedule follow-up contact ERS-ATS COPD Guidelines Management of stable COPD  Pharmacological therapy  Long-term oxygen therapy  Pulmonary rehabilitation  Nutrition  Surgery in and for COPD  Sleep  Air travel ERS-ATS COPD Guidelines Management of stable COPD  Pharmacological therapy  Long-term oxygen therapy  Pulmonary rehabilitation  Nutrition  Surgery in and for COPD  Sleep  Air travel ERS-ATS COPD Guidelines Pharmacological therapy (1)  The medications for COPD currently available can reduce or abolish symptoms, increase exercise capacity, reduce the number and severity of exacerbations, and improve health status.  At present, no treatment has been shown to modify the rate of decline in lung function.  The change in lung function after brief treatment with any drug does not help in predicting other clinically related outcomes.  The inhaled route is preferred. ERS-ATS COPD Guidelines Pharmacological therapy (2)  Changes in forced expiratory volume in one second (FEV1) following bronchodilator therapy can be small but are often accompanied by larger changes in lung volume, which contribute to a reduction in perceived breathlessness.  Combining different agents produces a greater change in spirometry and symptoms than single agents alone.  Three types of bronchodilators are in common clinical use: βagonists, anticholinergic drugs and methylxanthines. ERS-ATS COPD Guidelines Pharmacological therapy (3) Bronchodilators  Short-acting bronchodilators can increase exercise tolerance acutely in COPD.  Anticholinergics given q.i.d. can improve health status over a 3-month period.  Long-acting inhaled β-agonists improve health status, possibly more than regular ipratropium. Additionally, these drugs reduce symptoms, rescue medication use and increase the time between exacerbations.  Combining short-acting agents (salbutamol/ipratropium) produces a greater change in spirometry over 3 months than either agent alone.  Combining long-acting inhaled β-agonists and ipratropium leads to fewer exacerbations than either drug alone.  Combining long-acting β-agonists and theophylline produces a greater spirometric change than either drug alone.  Tiotropium improves health status and reduces exacerbations and hospitalisations compared with both placebo and regular ipratropium. ERS-ATS COPD Guidelines Pharmacological therapy (4) Glucocorticoids  Glucocorticoids act at multiple points within the inflammatory cascade, although their effects in COPD are more modest compared with bronchial asthma.  In patients with more advanced disease (usually classified as an FEV1 <50% predicted), there is evidence that inhaled corticosteroids can reduce the number of exacerbations per year. ERS-ATS COPD Guidelines Pharmacological Therapy (6) Effects on commonly used medications on important clinical outcomes in COPD Me d i ca t i o n Short -act i ng β-agoni st Iprat ropi um bromi de Long act i ng β-agoni st s Tiot ropi um Inhal ed cort i cost eroi ds Theophyl l i ne Me d i ca t i o n Short -act i ng β-agoni st Iprat ropi um bromi de Long act i ng β-agoni st s Tiot ropi um Inhal ed cort i cost eroi ds Theophyl l i ne FEV1 Yes (A) Yes (A) Yes (A) Yes (A) Yes (A) Yes (A) AE NA Yes Yes Yes Yes NA (B) (A) (A) (A) Lung vo l u m e Yes (B) Yes (B) Yes (A) Yes (A) NA Yes (B) Ex e rci se e n d u ra n ce Yes (B) Yes (B) Yes (B) Yes (B) NA Yes (B) Dysp n o e a Yes (A) Yes (A) Yes (A) Yes (A) Yes (B) Yes (A) Di se a se m o d i fi e r b y FEV1 NA No No NA No NA ERS-ATS COPD Guidelines Mo rt a l i t y Na NA NA NA NA NA HRQo L NA No (B) Yes (A) Yes (A) Yes (A) Yes (B) Si d e -e ffe ct s Some Some Mi ni mal Mi ni mal Some Import ant Management of stable COPD  Pharmacological therapy  Long-term oxygen therapy  Pulmonary rehabilitation  Nutrition  Surgery in and for COPD  Sleep  Air travel ERS-ATS COPD Guidelines Long-term oxygen therapy (1)  Long-term oxygen therapy (LTOT) improves survival, exercise, sleep and cognitive performance.  Reversal of hypoxaemia supersedes concerns about carbon dioxide (CO2) retention.  Arterial blood gas (ABG) is the preferred measure and includes acid-base information.  Oxygen sources include gas, liquid and concentrator.  Oxygen delivery methods include nasal continuous flow, pulse demand, reservoir cannulas and transtracheal catheter. ERS-ATS COPD Guidelines Management of stable COPD  Pharmacological therapy  Long-term oxygen therapy  Pulmonary rehabilitation  Nutrition  Surgery in and for COPD  Sleep  Air travel ERS-ATS COPD Guidelines Pulmonary rehabilitation  Pulmonary rehabilitation is a multidisciplinary programme of care that is individually tailored and designed to optimise physical and social performance and autonomy.  Pulmonary rehabilitation should be considered for patients with COPD who have dyspnoea or other respiratory symptoms, reduced exercise tolerance, a restriction in activities because of their disease, or impaired health status.  Pulmonary rehabilitation programmes include:       exercise training, education, psychosocial/behavioural intervention, nutritional therapy, outcome assessment, promotion of long-term adherence to the rehabilitation recommendations. ERS-ATS COPD Guidelines Management of stable COPD  Pharmacological therapy  Long-term oxygen therapy  Pulmonary rehabilitation  Nutrition  Surgery in and for COPD  Sleep  Air travel ERS-ATS COPD Guidelines Nutrition  Weight loss and a depletion of fat-free mass (FFM) may be observed in stable COPD patients.  Being underweight is associated with an increased mortality risk.  Criteria to define weight loss are:   Weight loss >10% in the past 6 months or >5% in the past month. Nutritional therapy may only be effective if combined with exercise or other anabolic stimuli. Underweight BMI <21 kg·m-2;age >50 yrs Normal weight BMI <21–25 kg·m-2 Overweight BMI <30 kg·m-2 Obese BMI 30 kg·m-2 ERS-ATS COPD Guidelines Management of stable COPD  Pharmacological therapy  Long-term oxygen therapy  Pulmonary rehabilitation  Nutrition  Surgery in and for COPD  Sleep  Air travel ERS-ATS COPD Guidelines Surgery in COPD (1)  Patients with a diagnosis of COPD have a 2.7–4.7-fold increased risk of post-operative pulmonary complications.  The further the procedure from the diaphragm, the lower the pulmonary complication rate.  Smoking cessation at least 4–8 weeks pre-operatively and optimisation of lung function can decrease post-operative complications.  Early mobilisation, deep breathing, intermittent positive-pressure breathing, incentive spirometry and effective analgesia may decrease postoperative complications. ERS-ATS COPD Guidelines Surgery in COPD (2) Algorithm for pre-operative testing for lung resection. DL,CO: carbon dioxide diffusing capacity of the lung; FEV1: forced expiratory volume in one second; ppo: predicted postoperative; V′O2,max: maximum oxygen consumption. ERS-ATS COPD Guidelines Surgery for COPD (1) Bullectomy Parame t e r Fav o u rab l e Un fav o u rab l e Clinical Rapid progressive dyspnoea despit e maximal medical t herapy Older age Ex-smoker Comorbid illness Cardiac disease Pulmonary hypert ension >10% weight loss Frequent respirat ory infect ions Chronic bronchit is Physiological Normal FVC or slight ly reduced FEV1 <35% pred FEV1 >40% pred Low t rapped gas volume Lit t le bronchoreversibilit y Decreased D L,CO High t rapped lung volume Normal or near normal D L,CO Normal Pa,O2 and Pa,CO2 Imaging Bulla >1/3hemit horax Vanishing lung syndrome CXR Poorly defined bullae Large and localised bulla wit h vascular crowding and normal Mult iple ill-defined bullae in CT pulmonary parenchyma around bulla underlying lung Vague bullae; disrupt ed Angiography Vascular crowding wit h preserved dist al vascular branching vasculat ure elsewhere W ell-localised mat ching defect wit h normal upt ake and Absence of t arget zones, poor Isot ope scan washout for underlying lung washout in remaining of lung CXR: chest radiography; CT: computed tomography; FVC: forced vital capacity; FEV 1: forced expiratory volume in one second; DL,CO: carbon monoxide diffusing capacity of the lung; Pa,O2; arterial oxygen tension; Pa,CO2; arterial carbon dioxide tension ERS-ATS COPD Guidelines Surgery for COPD (3) Lung Volume Reduction Surgery Parame t e r Clinical Fav o u rab l e Age <75yrs Clinical pict ure consist ent wit h emphysema Not act ively smoking (>3–6mont hs) Severe dyspnea despit e maximal medical t reat ment including pulmonary rehabilit at ion Requiring <20mg prednisone•day -1 Physiological FEV1 aft er bronchodilat or <45% pred Hyperinflat ion RV >150% TLC >100% pred Pa,O2 > 6kPa (45mmHg) Un fav o u rab l e Age > 75–80yrs Co-morbid illness which would increase surgical mort alit y Clinically significant coronary art ery disease Pulmonary hypert ension (PA syst olic >45, PA mean >35mmHg) Severe obesit y or cachexia Surgical const raint s Previous t horacic procedure Pleurodesis Chest wall deformit y FEV1 <20% pred and D L,CO <20% pred Decreased inspirat ory conduct ance Pa,CO2 < 8kPa (60mmHg) Post -rehabilit at ion 6-min walk >140m Low post -rehabilit at ion maximal achieved cycle ergomet ry wat t s # High-resolut ion comput ed t omography confirming severe Radiographical emphysema, ideally wit h upper lobe predominance Homogeneous emphysema and FEV1 <20% pred Non-upper lobe predominant emphysema and high post -rehabilit at ion cycle ergomet ry maximal achieved wat t age PA: alveolar pressure; RV: residual volume; TLC: total lung capacity; Pa,O2: arterial oxygen tension; Pa,CO2: arterial carbon dioxide tension; FEV1: forced expiratory volume in one second; DL,CO: carbon dioxide diffusing capacity of the lung. #: confirmed recommendations using NETT data or expert opinion. ERS-ATS COPD Guidelines Management of stable COPD  Pharmacological therapy  Long-term oxygen therapy  Pulmonary rehabilitation  Nutrition  Surgery in and for COPD  Sleep  Air travel ERS-ATS COPD Guidelines Sleep  Sleep in COPD is associated with oxygen desaturation, which is predominantly due to the disease itself rather than to sleep apnoea. The desaturation during sleep may be greater than during maximum exercise.  Sleep quality is markedly impaired in COPD, both subjectively and objectively.  Clinical assessment in all patients with COPD should include questions about sleep quality and possible co-existing sleep apnoea syndrome.  Management of sleep problems in COPD should particularly focus on minimising sleep disturbance by measures to limit cough and dyspnoea, and nocturnal oxygen therapy is rarely indicated for isolated nocturnal hypoxaemia.  Hypnotics should be avoided, if possible, in patients with severe COPD. ERS-ATS COPD Guidelines Management of stable COPD  Pharmacological therapy  Long-term oxygen therapy  Pulmonary rehabilitation  Nutrition  Surgery in and for COPD  Sleep  Air travel ERS-ATS COPD Guidelines Air travel  Commercial airliners can cruise at >12,000 m (>40,000 feet) as long as the cabin is pressurised from 1,800– 2,400 m (6,000–8,000 feet). This is equivalent to an inspired oxygen (O2) concentration at sea level of ~15%.  Patients with COPD can exhibit falls in arterial O2 tension (Pa,O2) that average 25 mmHg (3.3 kPa).  Pre-flight assessment can help determine O2 needs and the presence of co-morbidities.  Most airlines will provide supplemental O2 on request.  There is increasing evidence that patients on long flights may be at increased risk for deep vein thrombosis. ERS-ATS COPD Guidelines Exacerbation of COPD  Definition, evaluation and treatment  In-patient oxygen therapy  Assisted ventilation ERS-ATS COPD Guidelines Exacerbation of COPD  Definition, evaluation and treatment  In-patient oxygen therapy  Assisted ventilation ERS-ATS COPD Guidelines Definition, evaluation and treatment (1)  The definition of COPD exacerbation is an acute change in a patient’s baseline dyspnoea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in therapy.  Causes of exacerbation can be both infectious and noninfectious.  Medical therapy includes bronchodilators, corticosteroids, antibiotics and supplemental oxygen therapy. ERS-ATS COPD Guidelines Definition, evaluation and treatment (2)  Indications for hospitalisation of patients with a COPD exacerbation           Presence of high-risk co-morbid conditions, including pneumonia, cardiac arrhythmia, congestive heart failure, diabetes mellitus, renal or liver failure Inadequate response of symptoms to outpatient management Marked increase in dyspnoea Inability to eat or sleep due to symptoms Worsening hypoxaemia Worsening hypercapnia Changes in mental status Inability of the patient to care for her/himself Uncertain diagnosis Inadequate home care ERS-ATS COPD Guidelines Definition, evaluation and treatment (4)  Level I: outpatient treatment Patient education Check inhalation technique Consider use of spacer devices Bronchodilators Short-acting β2-agonist and/or ipratropium MDI with spacer or hand-held nebuliser as needed Consider adding long-acting bronchodilator if patient is not using it Corticosteroids (the actual dose may vary) Prednisone 30–40 mg per os q day for 10 days Consider using an inhaled corticosteroid Antibiotics May be initiated in patients with altered sputum characteristics Choice should be based on local bacteria resistance patterns Amoxicillin/ampicillin, cephalosporins Doxycycline Macrolides If the patient has failed prior antibiotic therapy consider: Amoxicillin/clavulanate Respiratory fluoroquinolones ERS-ATS COPD Guidelines Definition, evaluation and treatment (5)  Level II: treatment for hospitalised patient Bronchodilators Short acting β2-agonist (albuterol, salbutamol) and/or Ipratropium MDI with spacer or hand-held nebuliser as needed Supplemental oxygen (if saturation <90% ) Corticosteroids If patient tolerates, prednisone 30–40 mg per os q day for 10 days If patient can not tolerate oral intake, equivalent dose i.v. for up to 14 days Consider use inhaled corticosteroids by MDI or hand-held nebuliser Antibiotics (based on local bacteria resistance patterns) May be initiated in patients that have a change in their sputum characteristics (purulence and/or volume) Choice should be based on local bacteria resistance patterns Amoxicillin/clavulanate Respiratory fluoroquinolones (gatifloxacin, levofloxacin, moxifloxacin) If Pseudomonas spp. and/or other Enterobactereaces spp. are suspected, consider combination therapy ERS-ATS COPD Guidelines Definition, evaluation and treatment (6)  Level III: treatment in patients requiring special or intensive care unit Supplemental oxygen Ventilatory support Bronchodilators Short-acting β2-agonist (albuterol, salbutamol) and ipratropium MDI with spacer, two puffs every 2–4 h If the patient is on the ventilator, consider MDI administration, consider long-acting β-agonist Corticosteroids If patient tolerates oral medications, prednisone 30–40 mg per os q day for 10 days If patient can not tolerate, give the equivalent dose i.v. for up 14 days Consider use inhaled corticosteroids by MDI or hand-held nebuliser Antibiotics (based on local bacteria resistance patterns) Choice should be based on local bacteria resistance patterns Amoxicillin/clavulanate Respiratory fluoroquinolones (gatifloxacin, levofloxacin, moxifloxacin) If Pseudomonas spp. and or other Enterobactereaces spp. are suspected consider combination therapy ERS-ATS COPD Guidelines Exacerbation of COPD  Definition, evaluation and treatment  In-patient oxygen therapy  Assisted ventilation ERS-ATS COPD Guidelines In-patient oxygen therapy  The goal is to prevent tissue hypoxia by maintaining arterial oxygen saturation (Sa,O2) at >90%.  Main delivery devices include nasal cannula and venturi mask.  Alternative delivery devices include nonrebreather mask, reservoir cannula, nasal cannula or transtracheal catheter.  Arterial blood gases should be monitored for arterial oxygen tension ( Pa,O2), arterial carbon dioxide tension (Pa,CO2) and pH.  Arterial oxygen saturation as measured by pulse oximetry ( Sp,O2) should be monitored for trending and adjusting oxygen settings.  Prevention of tissue hypoxia supercedes CO 2 retention concerns.  If CO2 retention occurs, monitor for acidaemia.  If acidaemia occurs, consider mechanical ventilation. ERS-ATS COPD Guidelines Exacerbation of COPD  Definition, evaluation and treatment  In-patient oxygen therapy  Assisted ventilation ERS-ATS COPD Guidelines Assisted ventilation (1)  Noninvasive positive pressure ventilation (NPPV) should be offered to patients with exacerbations when, after optimal medical therapy and oxygenation, respiratory acidosis (pH <7.36) and or excessive breathlessness persist. All patients considered for mechanical ventilation should have arterial blood gases measured.  If pH <7.30, NPPV should be delivered under controlled environments such as intermediate intensive care units (ICUs) and/or high-dependency units.  If pH <7.25, NPPV should be administered in the ICU and intubation should be readily available.  The combination of some continuous positive airway pressure (CPAP) (e.g. 4–8 cmH2O) and pressure support ventilation (PSV) (e.g. 10–15 cmH2O) provides the most effective mode of NPPV. ERS-ATS COPD Guidelines Assisted ventilation (2)  Patients meeting exclusion criteria should be considered for immediate intubation and ICU admission.  Exclusion criteria include:           respiratory arrest, cardiovascular instability, impaired mental status, somnolence, inability to cooperate, copious and/or viscous secretions with high aspiration risk, recent facial or gastro-oesophageal surgery; craniofacial trauma and/or fixed naso-pharyngeal abnormality, burns, extreme obesity. In the first hours, NPPV requires the same level of assistance as conventional mechanical ventilation. ERS-ATS COPD Guidelines Assisted ventilation (3) Flow-chart for the use of noninvasive positive pressure ventilation (NPPV) during exacerbation of COPD complicated by acute respiratory failure. MV: mechanical ventilation; Pa,CO2: arterial carbon dioxide tension. ERS-ATS COPD Guidelines Patient section ERS-ATS COPD Guidelines Patient section  This updated document includes a patient section aimed at:     Providing practical information on all aspects of COPD. Promoting a healthy lifestyle to all patients afflicted with the disease. This section is available in English, French, German, Italian and Spanish. It includes printable files which can be directly distributed to patients. ERS-ATS COPD Guidelines ERS-ATS COPD Guidelines Website Address www.ersnet.org/copd Eur Respir J 2004; 23: 932–946 ERS-ATS COPD Guidelines